

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claim 1. (currently amended)      An enveloped pharmaceutical composition comprising:

    a first active available for immediate release, wherein over 80% of the first active is released within 60 minutes; and

    a second active for extended release selected from the group consisting of a decongestant, an antihistamine, an antitussive and mixtures thereof, wherein the first and the second active are disposed on separate carriers, wherein the second active comprises three or more layers of the second active agent and wherein over 80% of the second active is released between 90 minutes and 6 hours.

Claims 2-4. Cancelled

Claim 5. Cancelled.

Claim 6. (original)      The composition of claim 1, wherein immediate release is defined further as comprising release of over 90% of the first active within about 90 minutes.

Claim 7. Cancelled.

Claim 8. (original)      The composition of claim 1, wherein extended release is defined further as comprising release of over 90% of the second active within about 90 minutes to about 6 hours.

Claim 9. (previously presented)      The composition of claim 1, wherein the first active comprises guaifenesin.

Claim 10. (previously presented)      The composition of claim 1, wherein the first active comprises guaifenesin DC in a powder form.

Claim 11. (previously presented)      The composition of claim 1, wherein the first active comprises 211 mg of 95% guaifenesin.

Claim 12. (original)      The composition of claim 1, wherein the second active comprises a nasal decongestant.

Claim 13. (original) The composition of claim 1, wherein the second active comprises phenylephrine.

Claim 14. (original) The composition of claim 1, wherein the second active comprises phenylephrine as a sustained release bead.

Claim 15. (original) The composition of claim 1, wherein the second active comprises phenylephrine as a layered sustained release bead.

Claim 16. (original) The composition of claim 1, wherein the second active comprises three or more layers of phenylephrine on a bead.

Claim 17. (original) The composition of claim 1, wherein the first active is superposed on the second active.

Claim 18. (original) The composition of claim 1, comprising further one or more inactives.

Claim 19. (original) The composition of claim 1, wherein the first active for immediate release comprises a powder form and the second active comprises a beaded form.

Claim 20. (currently amended) An enveloped pharmaceutical composition comprising:

a first active available for immediate release, wherein over 80% of the first active is released within about 60 minutes; and

a second active available for extended release, wherein the first active effects a physiological result that improves the physiological action of the second active upon extended release.

Claim 21. (original) The composition of claim 20, wherein the first and second actives are enveloped in a single dose.

Claim 22-23 cancelled

Claim 24. Cancelled.

Claim 25. (original) The composition of claim 20, wherein immediate release is defined further as comprising release of over 90% of the first active within about 90 minutes.

Claim 26. (original) The composition of claim 20, wherein extended release is defined further as comprising release of over 80% of the second active within about 60 minutes to about 8 hours.

Claim 27. (original) The composition of claim 20, wherein extended release is defined further as comprising release of over 90% of the second active within about 90 minutes to about 6 hours.

Claim 28. (original) The composition of claim 20, wherein the second active for extended release is selected from the group consisting of a decongestant, an antihistamine, an expectorant, an antitussive and mixtures thereof.

Claim 29. (previously presented) The composition of claim 20, wherein the first active comprises guaifenesin.

Claim 30. (previously presented) The composition of claim 20, wherein the first active comprises Guaifenesin DC in a powder form.

Claim 31. (previously presented) The composition of claim 20, wherein the first active comprises 211 mg of 95% guaifenesin.

Claim 32. (original) The composition of claim 20, wherein the second active comprises a nasal decongestant.

Claim 33. (original) The composition of claim 20, wherein the second active comprises phenylephrine.

Claim 34. (original) The composition of claim 20, wherein the second active comprises phenylephrine as a sustained release bead.

Claim 35. (original) The composition of claim 20, wherein the second active comprises phenylephrine as a layered sustained release bead.

Claim 36. (original) The composition of claim 20, wherein the second active comprises three or more layers of phenylephrine on a bead.

Claim 37. (original) The composition of claim 20, wherein the first active is superposed on the second active.

Claim 38. (original) The composition of claim 20, comprising further one or more inactives.

Claim 39. (original) The composition of claim 20, wherein the first active for immediate release comprises a powder form and the second active comprises a beaded form.

Claim 40. (previously amended) An enveloped pharmaceutical composition comprising:

a first active packaged so that over 90 % of the first active is released within about 90 minutes; and

a second active comprises three or more layers of phenylephrine on a bead for extended release, wherein over 90% of the second active is released between about 1 and 6 hours.

Claim 41. (original) The composition of claim 40, wherein the first and the second actives are disposed on separate carriers.

Claim 42. (original) The composition of claim 40, wherein the first and second actives are enveloped in a single dose.

Claim 43. (original) The composition of claim 40, wherein the first and second actives are enveloped into a single dose.

Claim 44. cancelled

Claim 45. (original) The composition of claim 40, wherein over 80% of the first active is released within about 60 minutes.

Claim 46. (original) The composition of claim 40, wherein immediate release is defined further as comprising release of over 90% of the first active within about 60 minutes.

Claim 47. (original) The composition of claim 40, wherein extended release is defined further as comprising release of over 80% of the second active within about 60 minutes to about 8 hours.

Claim 48. (original) The composition of claim 40, wherein extended release is defined further as comprising release of over 90% of the second active within about 90 minutes to about 6 hours.

Claim 49. (previously presented) The composition of claim 40, wherein the first active comprises guaifenesin.

Claim 50. (previously presented) The composition of claim 40, wherein the first active comprises guaifenesin in a powder form.

Claim 51. (previously presented) The composition of claim 40, wherein the first active comprises 211 mg of 95% guaifenesin.

Claim 52. (original) The composition of claim 40, wherein the second active comprises a nasal decongestant.

Claim 53. (original) The composition of claim 40, wherein the second active comprises phenylephrine.

Claim 54. (original) The composition of claim 40, wherein the second active comprises phenylephrine as a sustained release bead.

Claim 55. (original) The composition of claim 40, wherein the second active comprises phenylephrine as a layered sustained release bead.

Claim 56. (original) The composition of claim 40, wherein the second active comprises three or more layers of phenylephrine on a bead.

Claim 57. (original) The composition of claim 40, wherein the first active is superposed on the second active.

Claim 58. (original) The composition of claim 40, comprising further one or more inactives.

Claim 59. (original) The composition of claim 40, wherein the first active for immediate release comprises a powder form and the second active comprises a beaded form.

Claim 60. (currently amended) An enveloped pharmaceutical composition comprising:  
a first active available for immediate effervescent release, wherein over 80% of the first active is released within about 60 minutes; and  
a second active in a mini-tab for extended release selected from the group consisting of a decongestant, an antihistamine, ~~an expectorant~~, an antitussive and mixtures thereof, wherein over 80% of the second active is release within about 90 minutes to about 6 hours.

Claim 61. (currently amended) An enveloped pharmaceutical composition comprising:  
a first active available for immediate release, wherein over 80% of the first active is released within about 60 minutes; and  
a second active for extended release on a carrier wherein the second active is selected from the group consisting of a decongestant, an antihistamine, ~~an expectorant~~, an antitussive and mixtures thereof wherein the first and second actives are different, wherein over 80% of the second active is release within about 90 minutes to about 6 hours.

Claims 62 – 80 cancelled.